Guggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price objective increased by equities research analysts at Guggenheim from $1,235.00 to $1,273.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 7.06% from the company’s current price.

A number of other research analysts also recently commented on the stock. Royal Bank Of Canada increased their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Finally, Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,266.74.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,189.06 on Monday. The business’s 50 day moving average is $1,098.66 and its two-hundred day moving average is $1,033.22. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The firm has a market cap of $1.12 trillion, a price-to-earnings ratio of 42.24, a PEG ratio of 1.47 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 35.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently modified their holdings of the business. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $30,000. Finally, Maseco LLP lifted its holdings in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.